Beam Therapeutics
OrganizationHeard in 4 episodes across 4 shows since Apr 2026
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base-editing technology to treat serious diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 1 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 2 |
| Nov 2026 | 1 |
Email alert
Email me when Beam Therapeutics comes up on a podcast
One email a week at most, with the new episodes that mention Beam Therapeutics. Free, no account needed, unsubscribe in one click.
What experts have said about Beam Therapeutics
3 statements · 1 negative · 1 mixed · 1 neutral
Beam Therapeutics filed a trade-secret lawsuit against Yoltec.
“Beam Therapeutics filed suit on September 25 in the U.S. District Court for the District of Massachusetts.”
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winnersListen at 11:49
Beam Therapeutics is a speculative investment.
“Beam is a speculative situation.”
Open the episode · Mad Money w/ Jim Cramer 4/28/26Listen at 36:08
Beam should be bought only if its treatment can save many lives.
“I would buy this if you thought that they've got something that can save a lot of lives. That's it. Otherwise, move on.”
Open the episode · Mad Money w/ Jim Cramer 4/28/26Listen at 36:17
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
4 episodes featuring Beam Therapeutics, newest first
- Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Oct 23, 2026
AI challenges biotech’s old company modelBiotech HangoutOct 23, 2026 - Oct 6, 2026
China’s biotech assets go global as Medicare pricing models shrinkBioCentury This WeekOct 6, 2026 - Apr 28, 2026
Cramer weighs a market reset against Iran-driven riskMad Money w/ Jim CramerApr 28, 2026